Patanjali CEO Acharya Balkrishna took to Twitter to announce that the company had provided the Ayush Ministry with all the information about the Coronil drug after it was asked to stop advertising and submit detailed information about it.
“We have overcome the communication gap and have 100% fulfilled all standard parameters for Randomised Placebo-Controlled Clinical Trials and have given all the information to the Ministry of Ayush,” he wrote in the tweet.
यह सरकार आयुर्वेद को प्रोत्साहन व गौरव देने वाली है जो communication gap था वह दूर हो गया है व Randomised Placebo Controlled Clinical Trials के जितने भी Standard Parameters हैं उन सबको 100% fullfill किया है इसकी सारी जानकारी हमने आयुष मंत्रालय को दे दी है @moayush @yogrishiramdev pic.twitter.com/0CAMPZ3xvR— Acharya Balkrishna (@Ach_Balkrishna) June 23, 2020
On Tuesday, in a big-bang announcement, Patanjali announced that it had found a medicine that will help prevent and cure Coronavirus. Patanjali claimed that its medicine, named as Coronil, can cure 100% Covid-19 patients in seven days.
Following the claims made by Patanjali, the Ayush Ministry asked the company to stop advertising such claims and to submit detailed report on the drug, adhering to the ministry guidelines.
The Ayush Ministry’s statement, read, “The concerned Ayurvedic drug manufacturing company has been informed that such advertisements of drugs including Ayurvedic medicines are regulated under the provisions of Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 and Rules thereunder and the directives issued by the Central Government in the wake of Covid outbreak. Ministry had also issued a Gazette Notification dated April 21, 2020 stating the requirements and the manner the research studies on Covid-19 with Ayush interventions/medicines should be undertaken.”
The government told Patanjali to submit details like name and composition of the medicines for Covid-19 treatment, the site where the research study was conducted, sample size, Institutional Ethics Committee clearance, CTRI registration and the results of the study.
Patanjali announced that the drug will soon be available at Patanjali stores in each district, tehsil and block.